Clinical Trial Update: Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III [Phase 3]

View source ↗

Summary

Phase III clinical trial evaluating GC101 gene therapy via intrathecal injection for type 2 spinal muscular atrophy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• GC101 Gene Therapy (GC101)

Snippet

Sponsor: GeneCradle Inc | Conditions: SMA - Spinal Muscular Atrophy | Phase 3 | Status: RECRUITING